Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/6/2025

Target Blood Pressure for Patients with Diabetes and Chronic Kidney Disease

Primary Guideline Recommendations

  • The European Society of Cardiology recommends a blood pressure target of systolic <130 mmHg and diastolic <80 mmHg for patients with diabetes and chronic kidney disease, with the goal of reducing microvascular and macrovascular complications 1, 2, 3, 4
  • The target blood pressure for patients with diabetes and chronic kidney disease should be lower than the target for elderly patients, with a systolic goal of <130 mmHg and a diastolic goal of <80 mmHg 1, 2, 3, 4

Treatment Approach

  • A RAAS blocker, such as an ACE inhibitor or ARB, is recommended as first-line therapy for patients with diabetes and chronic kidney disease, particularly in the presence of proteinuria or microalbuminuria 1, 3
  • Combination therapy with a RAAS blocker and either a calcium channel blocker or thiazide/thiazide-like diuretic is typically required to achieve target blood pressure in patients with chronic kidney disease 1, 3

Critical Pitfalls to Avoid

  • Lowering systolic blood pressure below 120 mmHg is not recommended, as it may increase the risk of hypoperfusion in patients with chronic kidney disease 1, 2, 4
  • Lowering diastolic blood pressure below 70 mmHg is not recommended, as it may increase cardiovascular risk in patients with chronic kidney disease 4

Supporting Evidence Quality

  • The 2019 ESC/EASD guidelines recommend blood pressure control to <140/90 mmHg to reduce stroke, coronary events, and kidney disease in diabetic patients, with a stronger recommendation for more intensive control to <130/80 mmHg in high-risk patients like those with diabetes and chronic kidney disease 2, 4
  • The ACCORD trial showed no harm from targeting <130 mmHg systolic in diabetic patients, though additional benefit was limited 5

Target Blood Pressure for Patients with CKD and Diabetes

Guideline-Based Recommendations

  • The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines acknowledge that patients with diabetes represent a subpopulation where evidence supporting the <120 mmHg target is less rigorous, making the risk-benefit ratio uncertain 6
  • The SPRINT trial, which forms the basis for the <120 mmHg recommendation, explicitly excluded patients with diabetes 7
  • The American College of Cardiology (ACC) and American Heart Association (AHA) recommend a blood pressure target, but the specific target for patients with CKD and diabetes is supported by evidence from trials such as the ACCORD trial, which showed no overall cardiovascular benefit at the <120 mmHg target, though stroke reduction was observed 7

Treatment Approach

  • The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend first-line therapy with a RAAS blocker (ACE inhibitor or ARB), particularly if proteinuria or microalbuminuria is present, although this specific information is not directly cited, the use of RAAS blockers is supported by 6 and 7

REFERENCES

← Return to Home